e-ISSN: 2717-7149
  • Home
  • About The Journal
  • Editorial Board
  • Instructions for Authors
  • Contact
Current Issue
Ahead Of Print
Archive
Search
Most Popular
Download Articles Read Articles
Retina Arter Tıkanıklıkları ve Tedavisi...
Santral Retinal Ven Tıkanıklığı Güncel Tedavisi...
Central Retinal Artery Occlusion As the Cause of Unilateral Concentric Narrowing of Visual Field and Presence of Cilioretinal Artery...
Bilateral Optic Disc Drusen
Vascular Endothelial Growth Factor and Anti VEGF Agents...
Central Retinal Artery Occlusion As the Cause of Unilateral Concentric Narrowing of Visual Field and Presence of Cilioretinal Artery...
Retina Arter Tıkanıklıkları ve Tedavisi...
Morning Glory Syndrome Associated with Retinochoroidal Coloboma...
Santral Retinal Ven Tıkanıklığı Güncel Tedavisi...
Bilateral Optic Disc Drusen
PureSee Kesintisiz Yüksek Kalitede Görüş
Retina-Vitreous 2023 , Vol 32 , Num 1
Turkish Abstract Abstract Free Full Text English Similar Articles Mail to Author
The Effects of Re-vitrectomy and Intravitreal anti-VEGF Treatments on Visual Outcome in Diabetic Vitreous Hemorrhage After Pars Plana Vitrectomy
Erol Havuz
Asst. Prof. Dr., University of Health Sciences, Samsun Training and Research Hospital, Department of Ophthalmology Samsun, Türkiye DOI : 10.37845/ret.vit.2023.32.5 Purpose: This study analyzed the effects of re-vitrectomy and intravitreal anti-VEGF treatments and other factors on visual acuity in vitreous hemorrhages (VH) in diabetic patients after vitrectomy.

Materials and Methods: VHs seen in vitrectomized diabetic patients were reviewed retrospectively. Hemorrhages in post vitrectomy diabetic vitreous hemorrhage (PDVH) were classified in three groups as moderate, marked and severe. One group of patients was treated with re- PPV, and the other had intravitreal anti-VEGF. Best-corrected visual acuity (BCVA), HbA1C levels, and anti-VEGF treatments up to the development of VH were evaluated during the one-year follow-up of the patients.

Results: A total of 16 patients with PDVH (10 females and six males) were examined. Ten (62.5%) patients were treated with anti-VEGF and 6 (37.5%) with re-PPV. The mean age of the patients was 63.5±8.9 years, and there was no difference between the two treatment groups in terms of age (p=0.087), HbA1c (p=0.609), previous anti-VEGF treatments (p=0.488), and VH severity (p=0.091). A statistically significant difference was found between the baseline visual acuity values between the groups (p=0.016). The mean of the anti-VEGF group was 0.96 logMAR, while the mean of the re-PPV group was 1.33 logMAR (worse). There was no difference between the mean visual outcomes of the two groups at the end of six months (p=0.157) and one year (p=0.309).

Conclusion: Since there was no difference between the two treatment modalities in terms of change in BCVA, minimally invasive intravitreal anti-VEGF therapy seems to be an alternative to re-vitrectomy in the treatment of PDVH. Keywords : Anti-VEGF therapy, diabetic retinopathy, re-vitrectomy, vitreous hemorrhage, visual outcomes

PureSee Kesintisiz Yüksek Kalitede Görüş
Home
About The Journal
Editorial Board
Instructions for Authors
Contact